Today's Information |
Provided by: Bora Pharmaceuticals Co., LTD. | |||||
SEQ_NO | 12 | Date of announcement | 2022/06/14 | Time of announcement | 21:21:34 |
Subject | The Company's Board of Directors passes the reolution to increase cash capital for the subsidiary | ||||
Date of events | 2022/06/14 | To which item it meets | paragraph 20 | ||
Statement | 1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.):Bora Biologics Co., Ltd. 2.Date of occurrence of the event:2022/06/14 3.Volume, unit price, and total monetary amount of the transaction: Volume: 39,415,000 unit Unit price:NTD 28 Total monetary amount:NTD 1,103,620,000 4.Trading counterparty and its relationship to the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): Bora Biologics Co., Ltd. Its relationship to the Company: Subsidiary 5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary value of transfer:Not applicable 6.Where an owner of the underlying assets within the past five years has been an related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship to the Company at the time of the transaction: Not applicable 7.Matters related to the current disposal of creditors' rights (including types of collaterals of the disposed creditor's rights; if creditor's rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor's rights, currently being disposed of, over such related party:Not applicable 8.Profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status of recognition shall be listed and explained):Not applicable 9.Terms of delivery or payment (including payment period and monetary value), restrictive covenants in the contract, and other important terms and conditions:In accordance to Bora Biologics Co., Ltd.'s schedule of cash capital increase 10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making unit:In accordance with the Company's Procedures for Acquisition or Disposal of Assets, it is approved by the audit committee and be submitted to and approved by the Board of Director. 11.Net worth per share of the Company's underlying securities acquired or disposed of:NA 12.Cumulative no.of shares held (including the current transaction), their monetary value, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment: Cumulative no. of shares held: 39,425,000 unit Monetary value: 1,103,720,000 Shareholding percentage: 65.69% Status of any restriction: none 13.Ratio of securities investment (including the current transaction) to the total assets and shareholder's equity of the parent company on the latest financial statements, and the operating capital on the latest financial statements, as of the present moment: Ratio of securities investment to total assets: 81.73% Ratio of securities investment to shareholder's equity of the parent company: 117.31% Operating capital: NTD 427,601 thousand 14.Broker and broker's fee:Not applicable 15.Concrete purpose or use of the acquisition or disposal: Raise cash capital for the operating asset contract 16.Whether the directors expressed any objection to the current transaction:None 17.Whether the counterparty of the current transaction is a related party:Yes 18.Date of the Board of Directors' resolution:2022/06/14 19.Date of ratification by supervisors or approval by the Audit Committee:2022/06/14 20.Whether the CPA issued an opinion on the unreasonableness regarding the current transaction:No 21.Name of the CPA firm:Fu An Accounting Firm 22.Name of the CPA:Wu, Hsiao Yun 23.License no.of the CPA:#5303 24.Any other matters that need to be specified:NA |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 13:42:09 UTC.